Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5964
    +0.0014 (+0.24%)
     
  • NZD/EUR

    0.5553
    +0.0013 (+0.23%)
     
  • ALL ORDS

    7,829.80
    -107.70 (-1.36%)
     
  • ASX 200

    7,568.70
    -114.30 (-1.49%)
     
  • OIL

    83.89
    +0.32 (+0.38%)
     
  • GOLD

    2,348.80
    +6.30 (+0.27%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    17,917.28
    -171.42 (-0.95%)
     
  • Hang Seng

    17,633.09
    +348.55 (+2.02%)
     
  • NIKKEI 225

    38,040.61
    +412.13 (+1.10%)
     
  • NZD/JPY

    93.0770
    +0.5810 (+0.63%)
     

Where Jazz Pharmaceuticals’ Defitelio, Vyxeos, and Prialt Stand

Where Jazz Pharmaceuticals’ Defitelio, Vyxeos, and Prialt Stand

Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of $36.2 million in the third quarter—compared to $31.2 million in the third quarter of 2017, which reflected ~17% YoY (year-over-year) growth. Defitelio reported net revenues of $111.7 million during the first nine months of 2018—compared to $97.4 million during the same period in 2017, which reflects ~15% YoY growth.